Johan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, Matthias Bödding, Özkan Yalkinoglu, Aliona Tappert, Andrea Seitzinger, Thomas Spangenberg, Deon Bezuidenhout, Justin Wilkins, Claude Oeuvray, Satish K Dhingra, Vandana Thathy, David A Fidock, Lisanne C A Smidt, Geert V T Roozen, Jan Pieter R Koopman, Olivia A C Lamers, Jeroen Sijtsma, Roos van Schuijlenburg, Els Wessels, Pauline Meij, Ingrid M C Kamerling, Meta Roestenberg, Akash Khandelwal
BACKGROUND: Cabamiquine is a novel antimalarial that inhibits Plasmodium falciparum translation elongation factor 2. We investigated the causal chemoprophylactic activity and dose-exposure-response relationship of single oral doses of cabamiquine following the direct venous inoculation (DVI) of P falciparum sporozoites in malaria-naive, healthy volunteers. METHODS: This was a phase 1b, randomised, double-blind, placebo-controlled, adaptive, dose-finding, single-centre study performed in Leiden, Netherlands...
July 3, 2023: Lancet Infectious Diseases